Gilead Sciences (GILD)

This week, five Biotechnology stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an "A" ("strong buy") or "B" overall ("buy").

Gilead Sciences Headed for New Highs

By Sam Collins, InvestorPlace Chief Technical Analyst Feb 12, 2013

Gilead Sciences is in an orderly bull market characterized by breakouts and breakaway gaps.

4 Things About This Rally That Terrify Me

By James Brumley, InvestorPlace Feature Writer Jan 30, 2013

When things look too good to be true, odds are the rug is about to get pulled out from underneath us -- if only a little bit.

Biotech Movers: Ariad Sinks, YM Soars

By Kyle Woodley, Senior Investing Editor, Kiplinger Dec 17, 2012

They were among the sector's big newsmakers last week, with Acadia, Oncolytics and Acura Pharmaceuticals.

Best & Worst Mutual Funds of 2012

By Susan J. Aluise, Aviation, Auto & Transportation Writer Dec 14, 2012

Mixed-cap, small-cap and biotech stocks were the places to be in mutual funds this year. But if you went for metals or were generally bearish, you lost out.

Consolidation Provides Good Entry Point for Top Biotech

By Sam Collins, InvestorPlace Chief Technical Analyst Nov 19, 2012

Gilead Sciences (NASDAQ:GILD) is in an orderly bull market characterized by breakouts followed by short-term consolidations.

My Brilliant Biotech Move for 2012

By James Brumley, InvestorPlace Feature Writer Nov 14, 2012

An overly helter-skelter year in the world of biotech stocks has been a stark reminder of a basic lesson that isn't followed enough: Keep it simple.

Profit From Volatility in Gilead and Celgene

By Michael Shulman, Editor, Options Income Blueprint Nov 13, 2012

The stocks popped Monday on good drug trials -- but these stocks should be on your radar for regular income through selling overheated puts.

Stocks at New Highs, New Lows for 11/13

By Alyssa Oursler, InvestorPlace Contributor Nov 13, 2012

Get the scoop on today's big moves. See which stock hit a new 52-week high, and one that found a new 52-week low.

Not Enough Spark From ‘Merger Monday’ — Monday’s IP Market Recap

By Marc Bastow, InvestorPlace Assistant Editor Nov 12, 2012

Wall Street saw three big deals in the mergers & acquisition world Monday, but the markets mostly shrugged with a flat performance.

Are Your ETFs as Diversified as You Think?

By Daniel Putnam, InvestorPlace Contributor Nov 9, 2012

ETFs should offer diversified exposure, but what happens when one or two stocks are running the whole show? It happens more than you think.

Biotechs Beat Q3 Earnings, Revenue Estimates

By Christopher Freeburn, InvestorPlace Writer Oct 24, 2012

Amgen, Gilead Science and Questcor Pharmaceuticals posted third-quarter earnings and revenue that beat Wall Street forecasts.

5 Funds That Will Profit From Mega-Trends

By Tom Taulli, InvestorPlace Contributor Oct 22, 2012

Rather than stock-picking to profit off today's major trends, investors can improve their chances by buying into these mutual funds and ETFs.

5 Most Reliable Buy-and-Hold Stocks

By James Brumley, InvestorPlace Feature Writer Oct 15, 2012

These names are the answer to a stock market that can't decide which direction it's going in. They're steady performers no matter what's happening around them.